AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest

AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest
0
(0)

Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking part in a Phase 1b/2 trial show.

The company will increase enrollment in this U.S. study to further evaluate these early outcomes.

“We have decided to expand the clinical trial to validate that early positive efficacy signal,” Laura Bonifacio PhD, vice president of Aravive, said in a press release. “If we continue to see a robust efficacy signal, we plan to work with FDA to explore the most efficient regulatory pathway to bring this drug to the patients in need.”

AVB-500 (previously known as AVB-S6-500) binds with high affinity to a protein called growth arrest-specific factor 6 (GAS6), preventing it from interacting with the AXL receptor and inhibiting the activation of the Gas6-AXL pathway, which plays a role in cancer progression.

High levels of GAS6 in the blood are associated with more aggressive cancer, resistance to treatment, and poorer outcomes in people with ovarian and breast cancer, and in those with acute myeloid leukemia.

Results of a previous Phase 1 trial (NCT03401528) in healthy volunteers showed that AVB-500 was safe and well-tolerated, and that it reduced the amount of GAS6 in the blood in a dose-dependent manner.

The therapy — which has the potential to work alone or in combination with standard of care — received fast track designation from the U.S. Food and Drug Administration for chemotherapy-resistant ovarian cancer in 2018.

The ongoing  Phase 1b/2 trial (NCT03639246) is evaluating the safety and efficacy of AVB-500 in combination with standard chemotherapy in women with platinum-resistant ovarian cancer. It started dosing patients at the beginning of the year and is still recruiting at locations across the U.S.

Its open-label Phase 1b portion divides patients into two groups. Each is being given AVB-500 in combination with a chemotherapeutic agent, either pegylated liposomal doxorubicin (PLD) or paclitaxel.

These preliminary efficacy findings, corresponding to the first 12 patients treated, showed that the percentage who responded to either combination is superior to that observed in similar patients given chemotherapy alone in the clinical setting.

Aravive plans to present detailed safety and efficacy trial data at a scientific conference later this year.

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.
Total Posts: 129
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and is currently working as a scientific writer, editor, and translator. As a writer for BioNews, she is fulfilling her passion for making scientific data easily available and understandable to the general public. Aside from her work with BioNews, she also works as a language editor for non-English speaking authors and is an author of science books for kids.
Latest Posts
  • Steps through OC program
  • SY-5609 shows promising activity
  • license agreement
  • BRAF mutations and cancer

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?